Phase I, multi-center, dose-escalation and dose-expansion study of IMP7068, a WEE1 inhibitor, in patients with advanced solid tumors

被引：2

作者：

Lin, C-C. ^{[1
]}

Grewal, J. ^{[2
]}

Baranda, J. C. ^{[3
]}

Schneider, R. E. ^{[4
]}

Zhang, J. ^{[5
]}

Bai, L-Y. ^{[6
]}

Yeh, Y-M. ^{[7
]}

Sommerhalder, D. ^{[8
]}

Li, G. ^{[9
]}

Shen, L. ^{[10
]}

Hsu, H-C. ^{[11
]}

Alese, O. ^{[12
]}

Yin, R. ^{[13
]}

Hsieh, C-Y. ^{[14
]}

Cai, S. X. ^{[15
]}

Tian, Y. E. ^{[16
]}

Xia, H. ^{[14
]}

Li, B. ^{[14
]}

Zhang, M. ^{[14
]}

Zhang, C. ^{[14
]}

机构：

[1] NTUH Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan

[2] Norton Canc Inst, Med Oncol, Louisville, KY USA

[3] Univ Kansas, Clin Res Ctr, Med Oncol Dept, Kansas City, KS USA

[4] Mary Crowley Canc Res Ctr, Outpatient Evaluat & Treatment Ctr Texas Oncol, Dallas, TX USA

[5] Fudan Univ, Shanghai Canc Ctr, Dept Oncol, Shanghai, Peoples R China

[6] China Med Univ Hosp, Div Hematol & Oncol, New Taipei, Taiwan

[7] NCKUH Natl Cheng Kung Univ Hosp, Oncol, Tainan, Taiwan

[8] NEXT Oncol, Oncol, San Antonio, TX USA

[9] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Gynaecol Oncol, Wuhan, Peoples R China

[10] Beijing Canc Hosp, Dept Digest Oncol, Beijing, Peoples R China

[11] Linkou Chang Gung Mem Hosp, Chang Gung Med Fdn, Oncol, Taoyuan, Taiwan

[12] Emory Univ Hosp, Hematol & Med Oncol, 1364 Clifton Rd NE, Atlanta, GA 30322 USA

[13] Sichuan Univ, West China Womens & Childrens Hosp, West China Univ Hosp 2, Dept Oncol & Chemoradiotherapy, Chengdu, Peoples R China

[14] IMPACT Therapeut Inc Shanghai, Clin Dev, Shanghai, Peoples R China

[15] IMPACT Therapeut Inc Shanghai, Dev, Shanghai, Peoples R China

[16] IMPACT Therapeut Inc Shanghai, Res, Shanghai, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.1848

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

662MO

引用

页码：S466 / S466

页数：1

共 50 条

[21] A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors
Padda, Sukhmani K.
Krupitskaya, Yelena
Chhatwani, Laveena
Fisher, George A.
Colevas, Alexander D.
Pedro-Salcedo, Melanie San
Decker, Rodney
Latz, Jane E.
Wakelee, Heather A.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (04) : 1013 - 1020
[22] Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study
Robert, Francisco
Sandler, Alan
Schiller, Joan H.
Liu, Glenn
Harper, Karen
Verkh, Lev
Huang, Xin
Ilagan, Jennifer
Tye, Lesley
Chao, Richard
Traynor, Anne M.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (04) : 669 - 680
[23] Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study
Francisco Robert
Alan Sandler
Joan H. Schiller
Glenn Liu
Karen Harper
Lev Verkh
Xin Huang
Jennifer Ilagan
Lesley Tye
Richard Chao
Anne M. Traynor
Cancer Chemotherapy and Pharmacology, 2010, 66 : 669 - 680
[24] A first-in-human phase I, dose-escalation and dose-expansion study of SY-5007, a highly potent and selective RET inhibitor, in Chinese patients with advanced RET positive solid tumors
Zhou, Caicun
Li, Wei
Zhang, Yiping
Song, Zhengbo
Wang, Yongsheng
Huang, Dingzhi
Ye, Feng
Wang, Qiming
Sun, Yinghui
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[25] A Phase I dose-escalation study of afatinib combined with nintedanib in patients with advanced solid tumors
Gordon, Michael S.
Springett, Gregory M.
Su, Yungpo Bernard
Ould-Kaci, Mahmoud
Wind, Sven
Zhao, Yihua
LoRusso, Patricia M.
FUTURE ONCOLOGY, 2015, 11 (10) : 1479 - 1491
[26] A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors
Sukhmani K. Padda
Yelena Krupitskaya
Laveena Chhatwani
George A. Fisher
Alexander D. Colevas
Melanie San Pedro-Salcedo
Rodney Decker
Jane E. Latz
Heather A. Wakelee
Cancer Chemotherapy and Pharmacology, 2012, 69 : 1013 - 1020
[27] Phase I/Ib dose-escalation study of avelumab in Chinese patients with advanced solid tumors
Wu, Yi-Long
Cheng, Ying
Chen, Huajun
Tu, Haiyan
Xu, Chongrui
Wang, Zhen
Liu, Ying
Xin, Ying
Lou, Haizhou
Wang, Wei
Chin, Kevin
Li, Dandan
Zhao, Di
Gao, Yanfei
Xu, Wenping
Pan, Hongming
FUTURE ONCOLOGY, 2022, 18 (17) : 2053 - 2062
[28] A PHASE I DOSE-ESCALATION STUDY OF EMD 1214063, AN ORAL SELECTIVE CMET INHIBITOR, IN PATIENTS WITH ADVANCED SOLID TUMORS
Naing, A.
Falchook, G. S.
Fu, S.
Amin, H. M.
Piha-Paul, S. A.
Hong, D. S.
Tsimberidou, A. M.
Wheler, J. J.
Janku, F.
Klevesath, M. B.
Jego, V.
Johne, A.
Kurzrock, R.
ANNALS OF ONCOLOGY, 2012, 23 : 21 - 21
[29] A Phase I, Dose-Escalation Study of the Multitargeted Receptor Tyrosine Kinase Inhibitor, Golvatinib, in Patients with Advanced Solid Tumors
Molife, L. Rhoda
Dean, Emma Jane
Blanco-Codesido, Montserrat
Krebs, Matthew G.
Brunetto, Andre T.
Greystoke, Alastair Peter
Daniele, Gennaro
Lee, Lucy
Kuznetsov, Galina
Myint, Khin Than
Wood, Karen
de las Heras, Begona
Ranson, Malcolm Richard
CLINICAL CANCER RESEARCH, 2014, 20 (24) : 6284 - 6294
[30] First-in-human, phase 1, open-label, dose-escalation, dose-expansion study of ADCT901 as monotherapy in patients with select advanced solid tumors
Harvey, R. Donald
Falchook, Gerald Steven
Naqash, Abdul Rafeh
Kim, Joseph W.
Dowlati, Afshin
Le Bruchec, Yvan
Coudert, Isabelle
Ervin-Haynes, Annette L.
Sommerhalder, David
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)

← 1 2 3 4 5 →